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Aims Data are scarce on the epidemiology of atrial fibrillation (AF) in Europe. The aim of this study was to examine recent
trends in the incidence and prevalence of AF and project the prevalence to the year 2050.
Methods
and results
From 1991 to 2008 a total of 4905 residents of Reykjavik, Iceland were diagnosed with AF at the city’s main health
care centre. The age-standardized incidence of AF increased in women (0.9% per year, 95% CI 0.1–1.8) but not in
men (0.1% per year, 95% CI 20.6 to 0.9). The age-standardized prevalence increased per year by 1.8% (95% CI 1.3–
2.3) in men and 2.3% (95% CI 1.7–2.9) in women from 1998 to 2008. The number of adults with AF in Iceland is
projected to increase from 4495 (prevalence 2.0%) in 2008 to 11 088 (prevalence 3.5%) in 2050, if the incidence
of AF and mortality remain constant beyond 2008. However, if the incidence continues to increase as it has and
mortality decreases according to projections for the general population, the projected number will rise to 13 583
(prevalence 4.3%).
Conclusion In this study in a northern European population, the incidence of AF increased in women but not men from 1991 to
2008. The prevalence of AF is currently high and the number of patients with AF is expected to triple in the next four
decades. AF is already a serious public health problem and the burden of this disease could reach epidemic
proportions in the coming years.
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Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia in
clinical practice and is associated with an increased risk of stroke,
heart failure, dementia, and death.1,2 The current economic burden
of AF in Europe is substantial and this has widespread implications
for the planning of national health care systems.3 The number of
individuals diagnosed with conditions considered risk factors for
AF, such as ischaemic heart disease, heart failure, obesity, and dia-
betes, has been increasing in recent years.4– 6 It has been postu-
lated that the incidence of AF may be increasing as well,
although there are currently insufficient data to either support
or refute this theory.
Studies on trends in the incidence of AF in Europe have been
limited to hospital admissions which may underestimate the
burden of this arrhythmia.7– 9 One community-based study from
the USA showed an increase in the incidence of AF from 1980
to 2000 but two later studies did not demonstrate this same
trend.10– 12 The prevalence of AF has reportedly been increasing
over different time periods ranging from the late 1960s to the
turn of the twentieth century.13–16 More recent data, however,
have not been published. Lifetime risks for development of AF
are 1 in 4 for men and women 40 years of age and older and
AF is more common with older age.17 The age distribution of
populations in developed countries is expected to shift in the
coming years with older age groups becoming more prominent.
Predictions from the USA suggest that the number of persons
with AF in that country will increase three-fold from 2000 to
2050.10,18–19 Such long-term predictions have not been published
for European populations.
The aim of this study was to examine recent trends in the inci-
dence and prevalence of AF in the general population and to
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provide prevalence estimates for AF in Iceland through 2050. The
characteristics of the Icelandic population, regarding both genetic
make-up and risk of cardiovascular disease, are typical for northern
Europe.20– 21 Two-thirds of the population reside in the capital
Reykjavik, which has only one major health care centre. This was
a retrospective open cohort study on adult residents of Reykjavik.
Methods
Study design and population
From 1991 to 2008 the population of Reykjavik aged 20–99 years
increased from 99 221 residents to 145 907. The percentage of the
population 65 years of age or older was 16% in both 1991 and
2008. The Icelandic health care system has universal access, similar
to other countries in Europe. The two largest hospitals in Reykjavik
(Reykjavik City Hospital and Landspitalinn) were merged into the
Landspitali—The National University Hospital of Iceland in 2002.
This hospital is the main health care centre in Iceland and the only hos-
pital in Reykjavik with inpatient, outpatient, and emergency care ser-
vices. In addition, it is the only facility where elective direct current
(DC) cardioversion for AF is performed. A large proportion of patients
with AF in the Reykjavik area are therefore likely to have received care
at this hospital or one of its predecessors. Since 1 January 1987 a
computer-based database has been in use for all patient visits to the
hospitals (Reykjavik City Hospital and Landspitalinn, from 1987 to
2001, Landspitali—The National University Hospital of Iceland from
2002 to 2008), with information on diagnosis, coded according to
the International Classification of Diseases (ICD), and the dates of
patient encounters. All residents of Reykjavik 20–99 years of age
with a diagnosis of AF (ICD-9 code 427.9 or ICD-10 code I48)
between 1 January 1987 and 31 December 2008 were identified
from this database. Patients with only post-operative AF after open
heart surgery were not included, but no further attempt was made
to subclassify AF. An analysis on the validity of the AF diagnosis was
done and hospital charts of random 100 incident AF cases were
reviewed. All of them had an ECG confirmed diagnoses of AF. A
recent study from Malmo, Sweden also reported a high validity of
the diagnosis of AF from a national hospital discharge register.22 Pres-
ence of hypertension, ischaemic heart disease, heart valve disease,
heart failure, diabetes mellitus, stroke, and transient ischaemic attack
(TIA) was noted if patients had the corresponding diagnoses codes,
either preceding or during the same visit as the initial AF diagnosis
(see Appendix). Follow-up was performed for the outcome of death
up until 31 December 2008. Information on residency and date of
death was obtained from Statistics Iceland.
Statistical analysis
Changes in mean age at diagnosis of AF by year were assessed with
linear regression. Incidence and prevalence rates were calculated per
sex and age group (20–54, 55–64, 65–74, and 85–99 years of age).
The mid-year population of Reykjavik for the corresponding category
served as the denominator. These rates were then used to directly cal-
culate overall incidence and prevalence, age and sex standardized to
the 2008 Reykjavik census population. Trend in incidence was exam-
ined with the Poisson regression model and trend in prevalence with
the logistic regression model. Calendar year, sex, and age group
were entered as variables into the models. There was incomplete
data registration on incident cases in 2002 and 2003. We suspect,
although unable to confirm, that temporary changes in the cardiology
services after the merger of the Reykjavik City Hospital and
Landspitalinn in 2002 may have resulted in a registration error of AF
cases. Based on this, a decision was made to exclude these 2 years
from the regression analysis on incidence. Just over half of the patients
had more than one hospital visit with a diagnosis of AF during the study
period. The mean time between visits was 500 days, with 90% of them
occurring within 4 years of the first diagnosis of AF. Patients with a first
diagnosis of AF from 1 January 1987 to 31 December 1990 were
therefore excluded from incidence calculations to reduce the risk of
counting prevalent cases as incident. Statistical significance was set at
P, 0.05.
The prevalence of AF was also calculated using a prevalence model
previously described by Miyasaka et al.10 In this model the age- and
sex-specific prevalence of AF at each year is calculated based on the
following measures from the previous year: the prevalence and inci-
dence of AF, yearly mortality in the general population and the relative
risk of mortality for AF patients compared with the general population
(see further details in Supplementary material online). For example,
the prevalence of AF in 65-year-old men in 2009 was calculated
based on these measures in 64-year-old men in 2008. The earliest
available data on age- and sex-specific mortality in Reykjavik were
from 1997, so the model was used from this point on. The modelled
prevalence fit well with the earlier described calculated prevalence.
The model was then continued through to the year 2050. The pro-
jected prevalence rates were calculated in four different ways. First,
the incidence of AF was kept constant at the 2008 rate and mortality
at the average rate of 2006–2008. Second, the incidence was increased
per year according to the trend from 1991 to 2008 and mortality was
kept constant. Third, the incidence was kept constant and forecasts of
the mortality in the Icelandic population were used and finally with the
changes in both incidence and mortality. The relative risk of mortality
for AF patients was kept constant. The age- and sex-specific preva-
lence rates were applied to the corresponding medium variant of
the population estimates from Statistics Iceland to project the total
number of persons in Iceland expected to have AF in every year
from 2009 to 2050. We then determined the contribution of popu-
lation growth, changes in demographics and changes in prevalence
on the difference in the number of people with AF in 2050 compared
with 2008 (see Supplementary material online for further details).
All analyses were performed using SAS version 9.2 and R version
2.12.
Ethics
This study complied with the Declaration of Helsinki and was
approved by the Icelandic Data Protection Authority and the National
Bioethics Committee of Iceland.
Results
Baseline characteristics
A total of 4905 residents of Reykjavik aged 20–99 years were diag-
nosed with AF at Landspitali—The National University Hospital of
Iceland from 1991 to 2008, of which 59.0% were men (Table 1 and
Supplementary material online, Table S1). The mean age at diagno-
sis increased significantly from 69.3+12.3 years in 1991 to 71.9+
12.8 years in 2008 for men and from 76.5+10.6 to 78.6+11.1
for women (P, 0.001 for both sexes).
Incidence
The age- and sex-standardized incidence of AF per 1000 person-
years was 2.1 in 1991 and 2.4 in 2008. The relative increase in
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0.5% per year did not reach statistical significance (95% CI 20.1 to
1.0, P ¼ 0.08). In men the age-standardized incidence did not
change significantly (0.1% per year, 95% CI 20.6 to 0.9, P ¼
0.70) (Figure 1). Furthermore, there was no significant change in
all age groups in men except in those aged 85–99 years, where
the incidence increased by 3.8% per year (95% CI 1.8–5.8)
(Table 2 and Supplementary material online, Table S2). In women
the age-standardized incidence increased by 0.9% per year (95%
CI 0.1–1.8, P ¼ 0.004). In women under 65 years of age the
change in incidence was not significant but in those 65 years of
age or older the incidence increased by 2.1% per year (95% CI
1.1–3.0, P, 0.001). The difference in the trend in incidence
between these groups was significant (P ¼ 0.012).
Prevalence
From 1998 to 2008 the age- and sex-standardized prevalence of
AF increased from 1.5 to 1.9%. In 2008 the prevalence was 2.3
and 1.5% in men and women, respectively. The annual percentage
change was 2.0% (95% CI 1.6–2.4, P, 0.0001) overall, 1.8% (95%
CI 1.3–2.3, P, 0.0001) in men and 2.3% (95% CI 1.7–2.9, P,
0.0001) in women. When examined by age group, there was no
significant change in the prevalence of AF in both sexes 20–54
and 54–64 years of age. There was a greater increase in prevalence
with increasing age in both men and women and the association
was linear (P, 0.0001 and P ¼ 0.0027 for linear trend, respect-
ively). The prevalence increase was most pronounced in men
85–99 years of age, or 5.1% per year (95% CI, 3.6–6.6) (Table 3
and Supplementary material online, Table S3).
Prevalence projections
Applying the 2008 age- and sex-specific prevalence rates to the
Icelandic census population gave an estimate of 4495 individuals
20–99 years of age with a diagnosis of AF in Iceland. This
amounts to a prevalence of 2.0%. Using the prevalence model pre-
viously described and assuming that the incidence of AF and mor-
tality remains constant beyond 2008, the projected number of
adults with AF will be 7612 (prevalence 2.8%, 95% CI 2.7–2.8)
in 2030 and 11 088 (prevalence 3.5%, 95% CI 3.4–3.5) in 2050.
If the assumption is that incidence will remain constant but that
mortality changes according to projections for the general popu-
lation of Iceland, the total number of patients will be 7948 (preva-
lence 2.9%, 95% CI 2.8–2.9) in 2030 and 12 076 (prevalence 3.8%,
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Figure 1 The incidence of AF in Reykjavik, Iceland 1991–2008 overall and by sex. Age standardized to the Reykjavik census population in
2008.
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Table 1 Baseline characteristics of patients at diagnosis
of AF in Reykjavik, Iceland 1991–2008
Characteristic Men, n (%) Women,
n (%)
All, n (%)
Age, yearsa 70.4 + 13.6 76.6 + 11.6 73.0 + 13.1
Age group, years
20–55 354 (13) 106 (5) 460 (9)
55–64 472 (17) 161 (8) 633 (13)
65–74 785 (28) 468 (22) 1253 (26)
75–84 825 (29) 813 (39) 1638 (33)
85–99 378 (13) 543 (26) 921 (19)
Ischaemic heart disease 1182 (42) 723 (35)* 1905 (39)
Heart failure 661 (23) 563 (27) 1224 (25)
Valvular heart disease 170 (6) 138 (7) 308 (6)
Hypertension 637 (23) 594 (28)* 1231 (25)
Diabetes 255 (9) 164 (8)* 419 (9)
History of stroke or TIA 451 (16) 397 (19) 848 (17)
TIA, transient ischaemic attack.
aMean+ standard deviation.
*P, 0.05 for comparison between men and women, after controlling for age.
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95% CI 3.7–3.9) in 2050. With constant mortality but a continuing
rise in the incidence of AF in women by 0.9% per year, as was
evident from 1991 to 2008, the projected number of patients
will rise to 7990 (prevalence 2.9%, 95% CI 2.8–3.0) in 2030 and
12 540 (prevalence 3.9, 95% CI 3.9–4.0) in 2050. Finally, assuming
the incidence and mortality change in accordance with the trend in
incidence and mortality forecasts, the number of persons with AF
in Iceland is projected to be 8329 (prevalence 3.0%, 95% CI 3.0–
3.1) in 2030 and 13 583 (prevalence 4.3%, 95% CI 4.2–4.3) in 2050
(Figure 2). The predicted number of adults with AF therefore
exceeds the 2008 estimates by a range of 147–202% in the year
2050. In comparison the adult Icelandic population is expected
to increase by 39% in the same time period, from 229 458
persons in 2008 to 318 624 in 2050 (Figure 3). In 2008 the pro-
portion of patients with AF who were 80 years of age or older
was 40% but is expected to increase in 55% in 2050. The projected
increase in case load of AF patients would be driven by population
growth (19.1%), shifting of the age distribution (53.4%), and
changes in incidence and mortality (27.5%). Supplementary
material online, Table S4 presents projected number of persons
with AF for men and women separately.
Discussion
This large community-based study from Reykjavik, Iceland, shows
that from 1991 to 2008 the incidence of AF increased in women
but not in men. The prevalence of AF increased overall by 2%
per year during the last decade of the study. Assuming no
further change in incidence and mortality beyond 2008, the preva-
lence of AF in Iceland is projected to increase from 2.0% in 2008 to
3.5% in 2050. If, on the other hand, recent trends in the incidence
of AF continue and mortality changes as expected in the general
population, the projected prevalence will be as high as 4.3% in
2050. This corresponds to an increase in the number of adults
with AF by .200%. These are the first prevalence projections
for AF using trends in incidence and mortality forecasts.
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Table 2 Secular trends in the incidence of AF in Reykjavik, Iceland by sex and age group
1991–1993 1994–1996 1997–1999 2000–2002 2003–2005 2006–2008
All, age and sex standardized 2.2 (640) 2.3 (748) 2.4 (808) 2.3 (839) 2.2 (872) 2.3 (998)
Men, age standardized 2.6 (378) 2.9 (452) 2.7 (449) 2.7 (477) 2.6 (506) 2.6 (552)
Age group (years)
20–54 0.4 (41) 0.7 (79) 0.5 (62) 0.5 (64) 0.3 (46) 0.4 (62)
55–64 3.6 (63) 4.1 (72) 3.8 (69) 3.7 (77) 3.5 (85) 3.7 (106)
65–74 9.2 (124) 9.5 (139) 9.1 (139) 8.3 (130) 8.1 (126) 8.0 (127)
75–84 17.4 (110) 17.0 (117) 17.3 (133) 16.4 (142) 16.6 (161) 15.5 (162)
85–99 22.3 (40) 24.2 (45) 24.0 (46) 31.6 (64) 38.1 (88) 34.6 (95)*
Women, age standardized 1.8 (262) 1.8 (296) 2.1 (359) 2.0 (362) 1.8 (366) 2.1 (446)*
Age group (years)
20–54 0.1 (14) 0.2 (23) 0.2 (23) 0.2 (23) 0.1 (11) 0.1 (12)
55–64 1.1 (21) 1.5 (29) 1.2 (24) 1.3 (29) 0.8 (21) 1.3 (37)
65–74 3.8 (60) 4.3 (75) 4.8 (88) 4.5 (82) 4.2 (74) 5.0 (89)*
75–84 10.2 (97) 10.0 (104) 11.9 (135) 11.2 (139) 11.9 (162) 12.3 (176)
85–99 20.0 (70) 17.2 (65) 23.0 (89) 21.3 (89) 20.6 (98) 24.4 (132)
Values are given as incidence rate per 1000 person-years with number of cases observed in parentheses.
*P, 0.05 for trends across calendar-year of AF diagnosis by Poisson regression analysis.
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Table 3 Secular trends in the prevalence (%) of AF in
Reykjavik, Iceland by sex and age group
1998–
1999
2000–
2002
2003–
2005
2006–
2008
All, age and sex
standardized
1.6 1.7 1.8 1.9*
Men, age
standardized
1.9 2.1 2.2 2.3*
Age group (years)
20–54 0.3 0.4 0.3 0.3
55–64 2.5 2.8 2.8 2.7
65–74 6.3 6.9 7.0 7.5*
75–84 12.4 13.8 14.3 15.1*
85–99 18.0 21.0 24.6 27.8*
Women, age
standardized
1.2 1.3 1.4 1.5*
Age group (years)
20–54 0.1 0.1 0.1 0.1
55–64 0.8 1.0 0.8 0.8
65–74 2.6 2.9 2.9 3.3*
75–84 6.6 7.2 8.1 9.0*
85–99 15.0 15.1 15.9 17.5*
*P, 0.05 for trends across calendar-year by logistic regression analysis.
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Trends in the incidence of AF
The trend in the incidence of AF from 1991 to 2008 showed dis-
tinct patterns by sex and age groups. There was no significant
change in men except in the oldest age group, 85–99 years of
age where the increase was almost 4% per year. In women,
however, the overall incidence increased by 0.9% per year.
There was a slight but steady incidence in those younger than 65
years of age but a 2.1% increase per year in those 65 years of
age or older. The reason for the different trends by sex is not
clear. In the last decades the prevalence of ischaemic heart
disease increased to a similar degree in men and women in the
general population of Reykjavik.5 Furthermore in a population-
based study on a large cohort of citizens of Reykjavik, the preva-
lence of diabetes and obesity increased and blood pressure
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Figure 2 Projected burden of diagnosed AF in 20–99 year olds in Iceland 2008–2050 assuming no change in the incidence of AF and mor-
tality beyond 2008 and assuming a continued increase in incidence as evident in 1991–2008 and mortality according to projections for Iceland.
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decreased at a comparable rate in both sexes from 1981 to 2006.23
The observed trends in the incidence of AF might concievably
reflect trends in the prevalence of some newer risk factors for
AF not accounted for in population attributed risk models. At
present much of the population risk for AF remains unex-
plained.21,24 Studies have shown that the risk of AF is lower in
patients with hypertension or heart failure if the disease severity
is less and if drugs that suppress the renin–angiotensin system
are used for treatment.25– 28 In addition, the risk of AF after myo-
cardial infarction has decreased with the introduction of acute
reperfusion therapy.29 If treatment of men and women with
these disorders has differed this might in part help explain the
different trends in incidence of AF.
This study provides the most current analysis on the trends in
incidence of AF in a general population. Other studies from
Europe on trends in incidence of AF were based on hospital admis-
sions alone and showed an increase in hospitalized patients with
AF during the 1980s through 1990s.7– 9. It is not clear whether
this was due to a true increase in the incidence of AF or due to
changes in hospital admissions criteria. While this current study
is based on hospital records, it includes, in addition to admissions,
elective DC cardioversions, outpatient clinic, and emergency room
visits. A comprehensive community-based study from Olmsted
County in MN in the USA showed that the age- and sex-adjusted
incidence of AF increased by 0.6% per year in the period of 1980–
2000.10 In contrast to our study the trend reached significance in
men but not women, but the rate of increase was not different
between the sexes. The Olmsted County study and this current
one only partially overlap in time so it is possible that the trend
in incidence is truly changing. It would, in this regard, be of interest
to know if there was any difference in the trend in the first vs.
second half of the study from Olmsted County. In the ARIC
study there was no change in the age-specific incidence of AF
from 1987 to 2004.11 There are some possible explanations for
the difference between this study and the current one. The
study sample was considerably smaller in the ARIC study, with
680 patients with AF 65 years of age or older compared with
3812 in the current one. In addition, the trends were compared
in smaller age groups than in this study. It is therefore possible
that the sample sizes were not large enough to detect significant
trends. Finally, in a study from 1992 to 2002 on a 5% sample of
Medicare patients (age ≥65 years) in the USA, there was a
steady overall incidence.12 Data on trends by sex were not
published, making comparison with our study difficult.
Trends in the prevalence of AF
The prevalence of AF increased from 1998 to 2008 by 2% per year.
An increase in prevalence could be the result of increasing inci-
dence and/or improved survival. The trend in prevalence by age
groups in women reflected the change in incidence, with the
prevalence increasing in those 65 years of age or older. Similarly
in the oldest age group for men, who had an increase in incidence,
the prevalence increased although to a slightly greater degree.
However, the prevalence also increased in men 65–74 and
75–84 years of age, where the incidence was stable. There are
limited data on temporal changes in the mortality of AF patients
compared with the general population and specifically if there
has been any difference in the trend by sex.
Few previous studies have reported age- and sex-specific trends
in the prevalence of AF and none with as recent data as this
current one. In the Framingham Study and the Copenhagen City
Heart Study the prevalence of AF in middle-aged and elderly
men but not women increased significantly from the 1970 to
1990s.13 –14 It was postulated that this sex-specific trend may in
part result from improvement in survival after myocardial infarc-
tion, which had been greater in men than women. Even so, the
same trends were evident in men and women with no history of
this disease. Two more recent studies from the UK, from a
primary care setting, reported an increase in the prevalence of
AF in both sexes of all ages at the turn of the century.15– 16 The
annual percentage change in prevalence was more than double
of what we found and the change per year was even higher in
the earliest studies. Even though these studies have been con-
ducted in different settings, this might possibly be an indication
that the rise in the prevalence of AF is slowing.
Future projections
The prevalence of AF in both Europe and the USA was reported to
be 1% in the 1990s.18,28 In this study, the 2008 prevalence of AF
in Iceland was 2%. Even with no change in incidence and mortality
beyond 2008, it is estimated that the number of adults with AF in
Iceland will almost triple over the next four decades. This can be
attributed to the expected growth and ageing of the population.
If we also factor in the recent trend in the incidence of AF and
the projected decrease in mortality in the general population the
number goes up from 4495 in 2008 to 13 583 in 2050, an increase
in 202%. These are the first long-term prevalence projections for
AF in Europe, although there have been three published preva-
lence projections for AF from the USA, with the initial point
ranging from 1995 to 2005.10,18–19 All of them projected a
similar relative increase in the number of people with AF as in
our study, assuming no change in incidence of AF or mortality.
Only one of these studies assumed an increase in incidence and
none incorporated mortality projections into the prevalence
model as done in this current study. The projected absolute
number of people with AF differed between the studies. In the pre-
viously mentioned study from Olmsted County the projected
number was in the range of 12–16 million people in 2050, depend-
ing on the trends in incidence. The other two studies, from a health
maintenance organization in California and a national health insur-
ance database, projected lower numbers (around 6 and 8 million,
respectively). As is postulated in these studies, the difference could
be related to different study settings, race composition, or case
ascertainment. Our results most closely compared with the
study from Olmsted County. The Icelandic population is 1000
times smaller than the US population so the projected case load
in relative terms is similar between these studies.
If we apply our prevalence rates to Europe we roughly estimate
that there are currently 10 million Europeans diagnosed with AF
and that by 2050 this number could rise to a staggering 25–30
million.30 An increasing proportion of the AF population will be
over 80 years old. This has serious implications for the planning
of health and welfare systems in Europe. In addition to treating
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AF, efforts will need to focus on developing effective upstream
therapies to prevent the disease and a more aggressive approach
to decrease the risk of serious complications such as stroke. In
this regard, a stricter adherence to practice guidelines for AF is
imperative as current data indicate that the use of anticoagulation
therapy to prevent stroke is significantly underutilized.31
Study limitations and strengths
There are clear limitations to this analysis. We did not exclude
those with secondary causes of AF other than recent cardiac
surgery. The diagnosis of AF was only acquired through hospital
records, which likely underestimates the incidence of AF in the
population. However, the diagnosis was not only obtained from
hospital admissions, but also from emergency room and outpatient
clinic visits. We do not have information on how many cases were
missed as the only published study from Iceland on the prevalence
of AF reported rates from over 40 years ago.32 As previously men-
tioned, based on the structure of the health facilities in Reykjavik,
we believe that the majority of patients with AF receive care at the
city’s only hospital. In support of that, our incidence and preva-
lence rates were higher than in other studies based only on hospi-
tal admissions and compared more closely to studies that
additionally had information from non-hospital-based phys-
icians.7– 9,33 Patients with asymptomatic AF are likely to be under-
represented in a study such as this. An increase in hospital coding
for AF diagnosis and awareness of AF leading to an increase in ECG
use could confound the observed trend in incidence of AF.
However, if this was a major factor we would have expected to
see an increase in incidence in both men and women.
This was an open cohort study which also has some limitations.
If the immigration or emigration rates are high, then changes
observed in the incidence or prevalence of AF could be because
the composition of study population was changing by year.
However, during our study period the net migration rate in Reykja-
vik was ,1%. Finally, the population of Iceland is largely Caucasian
so these results might not be directly applicable to other ethnic
groups in Europe.
This analysis also has important strengths. The study population
consisted of two-thirds of the Icelandic population and is therefore
a good representative of the nation as a whole. All the data from
the hospital database and from Statistics Iceland have been gath-
ered and registered prospectively. As all inhabitants of Iceland
have personal identification numbers the databases could be
easily linked and there was no loss to follow-up. The length of
the study period and the number of cases in the study are impor-
tant when trying to determine trends by subgroups.
Conclusion
The age-standardized incidence of AF in Reykjavik, Iceland,
increased in women but not men from 1991 to 2008. In the last
decade the prevalence of AF increased by a fifth in both sexes.
The number of adults with AF in Iceland is projected to triple in
the next four decades and an increasing proportion of this popu-
lation will be of very old age. AF is already a serious public
health problem and the burden of this disease could reach epi-
demic proportions in the coming years.
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Appendix
Hypertension: ICD-9 401-405. ICD-10 I10-15.
Ischaemic heart disease: ICD-9 410-414. ICD-10 I20-25.
Mitral and aortic valvular heart disease: ICD-9 394-369, 424.0, 424.1.
ICD-10 I05, I06, I34, I35.
Heart failure: ICD-9 428. ICD-10 I50.
Diabetes mellitus: ICD-9 249, 250. ICD-10 E10-14.
Stroke and transient ischaemic attack: ICD-9 430-434, 435, 436.
ICD-10 G45, I60-64.
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